For the quarter ending 2025-09-30, AXSM made $170,992,000 in revenue. -$47,229,000 in net income. Net profit margin of -27.62%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 170,992,000 | 150,042,000 | 121,463,000 | 92,305,000 |
| Cost of revenue (excluding amortization and depreciation) | 11,912,000 | 13,448,000 | 9,789,000 | 8,288,666.667 |
| Research and development | 40,162,000 | 49,541,000 | 44,785,000 | 47,229,666.667 |
| Selling, general and administrative | 150,235,000 | 130,280,000 | 120,787,000 | 105,265,000 |
| Loss in fair value of contingent consideration | 13,185,000 | -8,102,000 | 1,512,000 | 3,911,000 |
| Intangible asset amortization | 1,607,000 | 1,589,000 | 1,572,000 | 1,595,333.333 |
| Total operating expenses | 217,101,000 | 186,756,000 | 178,445,000 | 166,289,666.667 |
| Loss from operations | -46,109,000 | -36,714,000 | -56,982,000 | -72,646,000 |
| Interest expense, net | -1,120,000 | -1,834,000 | -2,431,000 | -1,530,333.333 |
| Loss on debt extinguishment | - | -10,385,000 | - | - |
| Loss before income taxes | -47,229,000 | -48,933,000 | -59,413,000 | -74,176,333.333 |
| Income tax benefit | - | -960,000 | - | - |
| Income tax benefit | - | -960,000 | - | 21,250 |
| Net loss | -47,229,000 | -47,973,000 | -59,413,000 | -74,204,666.667 |
| Net loss per common share, basic | -0.94 | -0.97 | -1.22 | -1.55 |
| Net loss per common share, diluted | -0.94 | -0.97 | -1.22 | -1.55 |
| Weighted average common shares outstanding, basic | 50,021,851 | 49,442,001 | 48,871,163 | -75,422 |
| Weighted average common shares outstanding, diluted | 50,021,851 | 49,442,001 | 48,871,163 | -75,422 |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)